Total Research Group, LLC

Miami, Florida 33126

6 studies enrolling now · 13 studies all time

What they study most

ADPKD, Autosomal Dominant Polycystic Kidney, COVID-19, Chronic Kidney Disease, End Stage Kidney Disease, Focal Segmental Glomerulosclerosis, Heart Failure, Hyperphosphatemia, Kidney Disease, Chronic, Obesity, Proteinuric Kidney Disease, Proteinuric Kidney Diseases

Studies at this site

• PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease — Recruiting now
• A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) — Recruiting now
• Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease — Running, not enrolling
• A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis — Completed
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease — Completed
• Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy — Completed
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease — Stopped early
• COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 — Stopped early